Crescent Biopharma, Inc. SEC filings CBIO
Crescent Biopharma, Inc. has 676 filings in SEC EDGAR's recent list, going back to Jul 10, 2003. Its latest annual report, Form 10-K, was filed on Feb 26, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Jul 30, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 15, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| S-8 | Employee stock plan registration | Sep 18, 2026 | — |
| POS AM | Filing | Jul 30, 2026 | — |
| 424B3 | Prospectus | Jul 30, 2026 | — |
| 424B5 | Prospectus supplement | Jul 15, 2026 | — |
| 424B5 | Prospectus supplement | Jul 14, 2026 | — |
| S-3 | Shelf registration | Jul 1, 2026 | — |
| 424B3 | Prospectus | Jun 22, 2026 | — |
| 424B3 | Prospectus | Apr 29, 2026 | — |
| 424B3 | Prospectus | Mar 17, 2026 | — |
| POS AM | Filing | Mar 3, 2026 | — |
| 424B3 | Prospectus | Feb 26, 2026 | — |
| S-8 | Employee stock plan registration | Feb 26, 2026 | — |
| 424B3 | Prospectus | Jan 15, 2026 | — |
| S-1 | Registration statement | Jan 7, 2026 | — |
| S-4 POS | Filing | Dec 12, 2025 | — |
| S-8 | Employee stock plan registration | Nov 6, 2025 | — |
| 424B3 | Prospectus | May 14, 2025 | — |
| S-4/A | Filing | May 12, 2025 | — |
| S-4/A | Filing | Apr 29, 2025 | — |
| S-4/A | Form s-4/a | Apr 4, 2025 | — |
| S-4 | Registration for a merger or exchange | Feb 18, 2025 | — |
| S-8 | Employee stock plan registration | Mar 27, 2024 | — |
| S-8 | Employee stock plan registration | Mar 29, 2023 | — |
| 424B5 | Prospectus supplement | Apr 28, 2022 | — |
| S-3 | Shelf registration | Mar 4, 2022 | — |
| S-8 | Employee stock plan registration | Mar 3, 2022 | — |
| S-8 | Employee stock plan registration | Mar 2, 2021 | — |
| 424B5 | Prospectus supplement | Oct 7, 2020 | — |
| S-8 | Employee stock plan registration | Feb 28, 2020 | — |
| S-3 | Shelf registration | May 17, 2019 | — |
| S-8 | Employee stock plan registration | Mar 6, 2019 | — |
| 424B5 | Prospectus supplement | Mar 21, 2018 | — |
| 424B5 | Prospectus supplement | Mar 19, 2018 | — |
| S-8 | Employee stock plan registration | Mar 6, 2018 | — |
| 424B5 | Prospectus supplement | Oct 6, 2017 | — |
| 424B5 | Prospectus supplement | Oct 6, 2017 | — |
| S-3 | Shelf registration | Sep 28, 2017 | — |
| 424B5 | Prospectus supplement | May 24, 2017 | — |
| 424B5 | Prospectus supplement | May 22, 2017 | — |
| S-8 | Employee stock plan registration | Mar 1, 2017 | — |
| 424B5 | Prospectus supplement | Jun 17, 2016 | — |
| 424B5 | Prospectus supplement | Jun 16, 2016 | — |
| 424B5 | Prospectus supplement | Jun 2, 2016 | — |
| 424B5 | Prospectus supplement | Mar 1, 2016 | — |
| S-8 | Employee stock plan registration | Feb 29, 2016 | — |
| S-8 | Employee stock plan registration | Aug 6, 2015 | — |
| S-3 | Shelf registration | Mar 17, 2015 | — |
| S-8 | Employee stock plan registration | Jan 10, 2014 | — |
| 424B4 | Prospectus | Jan 10, 2014 | — |
| S-1/A | Amended registration statement | Jan 7, 2014 | — |
| S-1/A | Amended registration statement | Dec 20, 2013 | — |
| FWP | Free writing prospectus | Nov 7, 2013 | — |
| S-1/A | Amended registration statement | Oct 31, 2013 | — |
| S-1/A | Amended registration statement | Oct 28, 2013 | — |
| S-1 | Registration statement | Oct 4, 2013 | — |
Showing 55 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CBIO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Cayman Islands
- Headquarters
- Waltham, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1253689
- Former names
- GLYCOMIMETICS INC (until Jun 23, 2025)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.